SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT.X) is trending as traders discuss its potential for a breakout, pointing to its strong chart setup and real-world partnerships. Community members are drawn to its low market cap, integration with Polkadot, and enterprise use cases, suggesting it may be undervalued. Volume is a key point of focus, as traders anticipate it could drive significant price movement.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a crypto emphasizing community, culture, and freedom within the cannabis space. Community members highlight Weedcoin as more than just a token, but a movement to connect people and ideas. With the hashtags #Weedcoin #CryptoCulture #Growth, the community is focused on building a positive and inclusive environment.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to positive Phase 3 trial results for its oral Wegovy pill, showing similar weight loss to the injectable version and potentially expanding market reach. The community is discussing the implications for market share and competition with Eli Lilly, especially with FDA approval expected soon. News of the trial results is driving optimism and renewed interest in NVO's potential.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as community members discuss its potential following news of quantum performance milestones and upcoming events involving key players like NVIDIA. Some traders are pointing to technical indicators and potential dilution from share issuance, while others remain bullish, citing government initiatives and long-term growth prospects in the quantum computing sector. The conversation also includes debate around valuation and comparisons to other companies in the space.

Honeywell International, Inc. is a software industrial company, which offers industry specific solutions to aerospace and automotive products and services. It operates through the following business segments: Aerospace Technologies, Industrial Automation, Building Automation, Energy and Sustainability Solutions, and Corporate and All Other. The company was founded by Albert M. Butz in 1906 and is headquartered in Charlotte, NC.

Honeywell International Inc

Honeywell ($HON) is trending amidst mixed sentiment, driven by anticipation of a potential company split and upcoming earnings. While some analysts express optimism regarding the industrial giant's growth and strategic moves, others point to potential headwinds like tariffs and weaker guidance, creating active discussion among retail traders regarding the stock's future performance and valuation.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as traders discuss its potential in AI, fueled by news of deepened partnerships and anticipation for upcoming product releases like the MI400 series. Community members are debating whether AMD can close the gap with its competitors, especially in light of potential shifts in market share within the AI chip market. Bullish sentiment persists with many seeing a buying opportunity amid the consolidation, while others express frustration with the stock's volatile price action and perceived underperformance relative to peers.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is trending as precious metals gain traction, driven by speculation around central bank policy and a weaker dollar, with some anticipating a rise to $30. The community is weighing the impact of potential tariff implications and analyzing technical indicators, with many expressing bullish sentiment on the stock's long-term prospects. Despite some concerns about rising costs and mixed opinions on recent strategic decisions, the overall conversation reflects optimism for Barrick's future amid favorable conditions for gold and silver.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending as investors discuss its potential following a disappointing report from MoonLake ($MLTX), which some believe makes $AVTX's data more interesting. The community is also actively discussing the high option prices and recent insider buying, with some anticipating a potential short squeeze due to the stock's low float and high short interest. Bullish sentiment is further fueled by analysts' Buy ratings and price target increases, focusing on the potential of AVTX-009 in treating hidradenitis suppurativa (HS).

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as investors anticipate upcoming data from their nomlabofusp clinical development program for Friedreich's ataxia, expected around the end of September. Community chatter highlights unusual options activity indicating bullish sentiment, with some speculating about the potential for significant price movement based on the data release. Others are analyzing volume spikes and insider trades, attempting to gauge the likelihood of positive clinical outcomes.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending following comments from Jim Cramer and ahead of upcoming earnings, sparking debate among investors. Community discussion centers on the validity of Cramer's concerns around dilution and revenue, the potential impact of a large private placement, and partnerships with tech giants like Microsoft and Nvidia. Optimists anticipate strong earnings and a rerating of the stock, while others express caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/09/3095729/33090/en/Axsome-Therapeutics-Provides-Update-on-the-New-Drug-Application-NDA-for-AXS-14-for-the-Management-of-Fibromyalgia.html">said</a> that it has received a Refusal-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its application for a drug approval to treat fibromyalgia.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.The agency said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.The FDA noted that it does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at eight weeks, and it used a flexible-dose paradigm.The agency, however, opined that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. Both studies yielded positive results. &nbsp;To address the FDA’s feedback, Axsome will conduct an additional controlled trial, utilizing a fixed-dose paradigm and a 12-week primary endpoint. The company anticipates initiating the new trial in the fourth quarter of 2025.CEO Herriot Tabuteau said that the company is “well-positioned” to initiate the new trial.Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from the disorder.On Stocktwits, retail sentiment around Axsome stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_09_at_8_04_44_AM_png_5593dd0fd5.webp" alt="AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the possibility for the company achieving profitability by the end of the year is “out the window.”<stembedurl>https://stocktwits.com/GrayCapital/message/617244353</stembedurl>Another user, however, brushed it off as a “small delay.”<stembedurl>https://stocktwits.com/cadbrad1/message/617242242</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has risen by about 28% this year and by about 56% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-us-china-talks/chlEazYRbyd">Dow Futures Edge Higher Ahead Of US-China Talks In London: WBD, Apple, Tesla Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability

The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.

Equity

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$115.00
Prev Close	$116.01
Open	$116.15
Dividend Yield	0.00%
50-Day Moving Average	$113.28
Beta	0.68
Avg. Volume	575,446.05
PE Ratio	-23.02

52-Week High	$139.13
52-Week Low	$75.56
Market Capitalization	$5.83B
EPS (Annual)	-$5.99
Price to Book	79.60
Revenue Per Employee	$564,704.25
Enterprise Value/EBITDA	N/A

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News

AXSM Axsome Therapeutics Inc